Du Pont drops suit against Syncor
Only weeks after filing a patent infringement suit against marketing partner Syncor International, Du Pont Pharmaceuticals this month terminated the litigation. In a joint press release, the two companies announced that their dispute has been resolved.
Only weeks after filing a patent infringement suit against marketing partner Syncor International, Du Pont Pharmaceuticals this month terminated the litigation. In a joint press release, the two companies announced that their dispute has been resolved. The conflict was a misunderstanding, according to Robert Funari, president and CEO of Syncor. The firms declined to provide further details on the matter.
The decision brings a quick end to a tussle that surprised market watchers. On June 17, North Billerica, MA-based Du Pont filed suit against Syncor with the Mexican Institute of Industrial Property, alleging that Syncors subsidiary, Syncor de Mexico, has illegally bought and sold Cardiolite kits, including counterfeit Cardiolite, in Mexico (SCAN 8/4/99). Syncor of Woodland Hills, CA, issued a strong denial of the charges, and filed a defense.
Both companies emphasized the importance of their U.S. relationship in resolving the dispute. The two firms rely heavily on each other: Syncor has been Du Ponts primary U.S. distributor of Cardiolite since the products launch, and distributes more than 80% of the unit doses sold in the U.S.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
